August 10, 2021

Sydnexis Executes Exclusive License with Santen

Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation, for Europe, Middle East and Africa.

Read More

August 10, 2021

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Bluestem Capital

Sydnexis today announced the completion of a $45 million Series B financing led by Visionary Ventures, Bluestem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Read More

August 10, 2021

Sydnexis Executes Exclusive License with Santen

Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation, for Europe, Middle East and Africa.

Read More

August 10, 2021

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Bluestem Capital

Sydnexis today announced the completion of a $45 million Series B financing led by Visionary Ventures, Bluestem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Read More

The Company

Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.

The Company

Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.

Our Mission

Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Myopia occurs in ~30-40% of children in the U.S. and E.U. and recent estimates suggest that number may be closer to 80% in Asia. Once considered a benign refractive condition myopia, even at low levels, is associated with numerous serious ophthalmic co-morbidities. Such ophthalmic co-morbidities include myopic macular degeneration, macular choroidal neovascularization, retinal detachment, glaucoma, and blindness. The greater the severity of myopia, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children.

Our Mission

Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Myopia occurs in ~30-40% of children in the U.S. and E.U. and recent estimates suggest that number may be closer to 80% in Asia. Once considered a benign refractive condition myopia, even at low levels, is associated with numerous serious ophthalmic co-morbidities. Such ophthalmic co-morbidities include myopic macular degeneration, macular choroidal neovascularization, retinal detachment, glaucoma, and blindness. The greater the severity of myopia, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children.